Evident inhibition/blockade of the viral RNA-dependent RNA polymerase (RdRp) of the newly-emerged fatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is considered one of the most promising and efficient approaches for developing highly potent remedies for Coronavirus Disease 2019 (COVID-19). However, almost all of the reported viral RdRp inhibitors (either repurposed or new antiviral drugs) lack specific selectivity against the novel coronaviral-2 RdRp and still at a beginning phase of advancement. In this complementary research study, the new pyrazine derivative cyanorona-20 was revisited with an update about its synthetic and toxicological data. This promising selective specific anti-COVID-19 compound is deemed to be the first distinctive derivative of favipiravir. Cyanorona-20, the unrivalled nucleoside/nucleotide analog, was designed, synthesized, characterized, computationally studied, and biologically evaluated for its anti-COVID-19/cytotoxic actions. The results of the biological assay displayed that cyanorona-20 surprisingly exhibited very high and largely significant anti-COVID-19 activities (anti-SARS-CoV-2 EC50 = 0.45 μM), and, in addition, it could be also a very promising guide and lead compound for the design and synthesis of new anti-SARS-CoV-2 and anti-COVID-19 agents through structural modifications and further computational studies. Further appraisal for the improvement of cyanorona-20 medication, through performing deeper in vivo biological evaluations and extensive clinical trials, is a prerequisite requirement in the coming days. In this short communication paper, the comprehensive chemicobiological data and information about the "Corona Antidote", cyanorona-20 compound, were briefly and collectively revisited and the synthetic and pharmacotoxicological data were updated.